60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or
the “Company”), a pharmaceutical company focused on developing new
medicines for infectious diseases, announced today that the U.S.
Food and Drug Administration (FDA) has granted a Type C meeting
with the Company to consult on the path forward in developing the
tafenoquine regimen of ARAKODA® for a potential
indication in treating hospitalized babesiosis patients. The
meeting will take place on January 15, 2024.
Tafenoquine is approved for malaria prophylaxis
in the United States under the product name ARAKODA. The safety of
the approved regimen of tafenoquine for malaria
prophylaxis has been assessed in five separate randomized,
double-blind, active comparator, or placebo-controlled trials for
durations of up to six months.
Tafenoquine has not been proven to be effective
for treatment or prevention of babesiosis and is not approved by
the FDA for such an indication.
The efficacy and safety of 8-aminoquinolines, a class of drugs
that includes tafenoquine and primaquine, for
prevention and treatment of malaria is well established. The
appearance of several case studies of tafenoquine
use for babesiosis in the literature suggests that the drug is
being used for this purpose in practice of medicine. The Company is
planning an adequate and well controlled clinical study to evaluate
this use systematically.
About Babesiosis
An estimated 47,000 cases of babesiosis (infections caused by
red blood cell parasites similar to malaria that are transmitted by
deer tick bites) occur in the United States each year and
the incidence rate is increasing.1 An estimated 10 percent of Lyme
disease patients are co-infected with babesiosis.2 The mortality
rate of babesiosis patients with cardiac complications approaches
10 percent.3
Anyone can get babesiosis, but it can be more severe in the
elderly, people who have had their spleen removed, and in people
who have weakened immune systems (for example, those who have
cancer, HIV/AIDS, or a transplant). Most cases occur in coastal
areas in the Northeast and upper Midwest, particularly in parts of
New England, New York State, New Jersey, Wisconsin, Minnesota and
in some European countries. In the Northeast, babesiosis occurs in
both inland and coastal areas including offshore islands, such as
Nantucket and Martha's Vineyard, which are off Massachusetts, as
well as Long Island and the Hudson Valley in New York State.
Hospitalizations as a result of babesiosis are usually seasonal,
occurring June through August. Clinical complications include
severe anemia, renal failure, cardiorespiratory failure, and
death.
Babesiosis is spread by the bite of an infected blacklegged
tick, Ixodes scapularis. It can also be spread by transfusion of
contaminated blood.
Babesiosis was designated a nationally notifiable disease in the
United States in 2011, meaning that states where it was reportable
were charged to voluntarily notify the Centers for Disease Control
and Prevention of cases.
About ARAKODA® (tafenoquine)
Tafenoquine was discovered by Walter
Reed Army Institute of Research and the current study was
funded by the United States Army Medical & Materiel
Development Activity. Tafenoquine was
approved for malaria prophylaxis in 2018 in the United
States as ARAKODA® and in Australia as
KODATEF®.
Both were commercially launched in 2019 and are currently
distributed through pharmaceutical wholesaler networks in each
respective country. They are available at retail pharmacies as a
prescription-only malaria prevention drug.
According to the Centers for Disease Control and
Prevention, the long terminal half-life
of tafenoquine, which is approximately 16
days, may offer potential advantages in less-frequent dosing for
prophylaxis for malaria. ARAKODA is not suitable for
everyone, and patients and prescribers should review the Important
Safety Information below.
Individuals at risk of contracting malaria are prescribed
ARAKODA 2 x 100 mg tablets once per day for three days (the loading
phase) prior to travel to an area of the world where malaria is
endemic, 2 x 100 mg tablets weekly for up to six months during
travel, then 2 x 100 mg in the week following travel.
ARAKODA® (tafenoquine) Important Safety
InformationARAKODA is an antimalarial indicated for the
prophylaxis of malaria in patients aged 18 years of age and
older.
Contraindications
ARAKODA® should not be administered to:
- Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or
unknown G6PD status;
- Breastfeeding by a lactating woman when the infant is found to
be G6PD deficient or if G6PD status is unknown;
- Patients with a history of psychotic disorders or current
psychotic symptoms; or
- Known hypersensitivity reactions to
tafenoquine, other 8-aminoquinolines, or any
component of ARAKODA®.
Warnings and Precautions
Hemolytic Anemia: G6PD testing must be
performed before prescribing ARAKODA® due to the risk of
hemolytic anemia. Monitor patients for signs or symptoms of
hemolysis.
G6PD Deficiency in Pregnancy or Lactation:
ARAKODA® may cause fetal harm when administered to a pregnant woman
with a G6PD-deficient fetus. ARAKODA® is not recommended during
pregnancy. A G6PD-deficient infant may be at risk for hemolytic
anemia from exposure to ARAKODA® through breast milk. Check
infant’s G6PD status before breastfeeding begins.
Methemoglobinemia: Asymptomatic elevations in
blood methemoglobin have been observed. Initiate appropriate
therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse
reactions have been observed in patients with a history of
psychosis or schizophrenia, at doses different from the approved
dose. If psychotic symptoms (hallucinations, delusions, or grossly
disorganized thinking or behavior) occur, consider discontinuation
of ARAKODA® therapy and evaluation by a mental health professional
as soon as possible.
Hypersensitivity Reactions: Serious
hypersensitivity reactions have been observed with administration
of ARAKODA®. If hypersensitivity reactions occur, institute
appropriate therapy.
Delayed Adverse Reactions: Due to the long
half-life of ARAKODA® (approximately 17 days), psychiatric effects,
hemolytic anemia, methemoglobinemia, and hypersensitivity reactions
may be delayed in onset and/or duration.
Adverse Reactions: The most common adverse
reactions (incidence greater than or equal to 1 percent) were:
headache, dizziness, back pain, diarrhea, nausea, vomiting,
increased alanine aminotransferase (ALT), motion sickness,
insomnia, depression, abnormal dreams, and anxiety.
Drug Interactions
Avoid co-administration with drugs that are substrates of
organic cation transporter-2 (OCT2) or multidrug and toxin
extrusion (MATE) transporters.
Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient
infant or infant with unknown G6PD status during treatment and for
3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees
Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at
1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing
information of ARAKODA® is located here.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes
in developing and marketing new medicines for the treatment and
prevention of infectious diseases that affect the lives of millions
of people. 60P successfully achieved FDA approval of its lead
product, ARAKODA® (tafenoquine), for malaria
prevention, in 2018. 60P also collaborates with prominent research
organizations in the U.S., Australia, and Singapore. 60P’s mission
has been supported through in-kind funding from the U.S. Department
of Defense and private institutional investors including Knight
Therapeutics Inc., a Canadian-based pan-American specialty
pharmaceutical company. 60P is headquartered in Washington D.C.,
with a majority-owned subsidiary in Australia. Learn more at
www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward‐looking
statements reflect the current view about future events. When used
in this press release, the words “anticipate,” “believe,”
“estimate,” “expect,” “future,” “intend,” “plan,” or the negative
of these terms and similar expressions, as they relate to us or our
management, identify forward‐looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current
beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: there is substantial doubt as
to our ability to continue on a going-concern basis; we might not
be eligible for Australian government research and development tax
rebates; if we are not able to successfully develop, obtain FDA
approval for, and provide for the commercialization of non-malaria
prevention indications for tafenoquine (ARAKODA®
or other regimen) or Celgosivir in a timely manner, we may not be
able to expand our business operations; we may not be able to
successfully conduct planned clinical trials; and we have no
manufacturing capacity which puts us at risk of lengthy and costly
delays of bringing our products to market. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange
Commission (SEC), including the information contained in the
final prospectus to our Registration Statement on Form S-1 (File
No.: 333-269483), as amended, initially filed with the SEC on
January 31, 2023 relating to our initial public offering, and our
subsequent Quarterly Report on Form 10-Q for the period ended June
30, 2023. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at www.sec.gov.
As a result of these matters, changes in facts, assumptions not
being realized or other circumstances, the Company’s actual results
may differ materially from the expected results discussed in the
forward-looking statements contained in this press release. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Media Contact:Sheila A. BurkeMethod Health
CommunicationsSheilaBurke-consultant@60degreespharma.com(484)
667-6330
Investor Contact:Patrick
Gaynespatrickgaynes@60degreespharma.com(310) 989-5666
1 DATA ON FILE2 DATA ON FILE3 DATA ON FILE
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From May 2024 to Jun 2024
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Jun 2023 to Jun 2024